| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0314c17f8ea3bab5fd7bba8cdda11ac2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06013 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate |
2016-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39de5c1d1a288588b77c2661967ae2e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcba50464d1d41cc7752ff27d07c5d1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c73b67a52ed3370a9775783b38532a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb72ae15783b637da55b53a323a67d96 |
| publicationDate |
2021-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2866957-T3 |
| titleOfInvention |
Hunter syndrome therapeutic agent and method of treatment |
| abstract |
A formulation for use in the treatment of Hunter syndrome, comprising a first composition for intravenous injection and a second composition for subcutaneous injection, wherein the first composition comprises iduronate-2-sulfatase consisting of at least one of the amino acid sequences of SEQ ID NO: 1 and 2; and wherein the second composition comprises iduronate-2-sulfatase consisting of at least one of the amino acid sequences of SEQ ID NO: 1 and 2; and wherein the first composition is injected intravenously once every two months or twice a month and the second composition is injected subcutaneously one to seven times a week, wherein the first composition is administered first, followed by the administration of the second composition. |
| priorityDate |
2015-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |